Effect of Pemafibrate, a Selective Peroxisome Proliferator-activated Receptor ? Modulator (SPPARM?), on the Lipid Profile, Liver Function, and Liver Fibrosis among Patients with Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. (2025). Translation: The University of Toledo Journal of Medical Sciences, 13(S3). https://doi.org/10.46570/utjms-2025-1397